Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants.
Adult
Aged
Alleles
DNA Mutational Analysis
Familial Mediterranean Fever
/ genetics
Female
Genetic Predisposition to Disease
Headache
/ genetics
Humans
Male
Middle Aged
Multiple Sclerosis
/ genetics
Mutation
NLR Family, Pyrin Domain-Containing 3 Protein
/ genetics
Optic Neuritis
/ genetics
Penetrance
Phenotype
Pyrin
/ genetics
Receptors, Tumor Necrosis Factor, Type I
/ genetics
Young Adult
Autoimmunity
Autoinflammation
CAPS
FMF
Multiple sclerosis
TRAPS
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
20 Jun 2020
20 Jun 2020
Historique:
received:
19
12
2019
accepted:
04
06
2020
entrez:
22
6
2020
pubmed:
22
6
2020
medline:
21
5
2021
Statut:
epublish
Résumé
Neurological manifestations and the co-occurrence of multiple sclerosis (MS) have been reported in patients with autoinflammatory diseases (AID) and variants of the NLRP3-, MEFV-, or TNFRSF1A gene. However, type and frequency of neurological involvement are widely undetermined. We assessed clinical characteristics of 151 (108 with MS) patients carrying NLRP3-, MEFV- and TNFRSF1A low-penetrance variants from the Institute of Clinical Neuroimmunology. We evaluated demographic, genetic, and clinical features with a focus on central nervous system (CNS) involvement including magnetic resonance imaging (MRI) results and cerebrospinal fluid (CSF) data. The disease course of AID patients with MS was compared to a matched MS control group without mutations. The genetic distribution comprised 36 patients (23%) with NLRP3- and 66 patients (43%) with TNFRSF1A low-penetrance variants as well as 53 (34%) patients carrying pathogenic mutations or low-penetrance variants in the MEFV gene. MS patients displayed most frequently the R92Q TNFRSF1A variant (n = 51; 46%) followed by the Q703K NLRP3 variant (n = 15; 14%) and the E148Q substitution (n = 9; 8%) in the MEFV gene. The disease course of MS was not influenced by the genetic variants and did not differ from MS patients (n = 51) without mutations. AID patients without MS most frequently harbored MEFV mutations (n = 19, 43%) followed by NLRP3- (n = 17, 39%) and TNFRSF1A (n = 8, 18%) low-penetrance variants. Sixteen (36%) of them suffered from severe CNS involvement predominantly recurrent aseptic meningoencephalitis and optic neuritis accompanied by abnormal MRI and CSF results. Severe CNS inflammation was associated with the Q703K allele. Headache was a highly prevalent neurological symptom (up to 74%), irrespective of the underlying genetic variation. The NLRP3 cohort without MS more frequently exhibited affections of the cranial nerves (CN) (p = 0.0228) and motor symptoms (p = 0.0455). Elevated acute-phase reactants were detected in all patients, and fever episodes were present in up to 50%. Arthralgias were the most frequently identified constitutional symptom among all subgroups. Our data highlight the high prevalence of neurological manifestations, including concomitant MS, among NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants. In particular, patients carrying the Q703K NLRP3 variant are at risk for severe CNS inflammation and CN affection.
Sections du résumé
BACKGROUND
BACKGROUND
Neurological manifestations and the co-occurrence of multiple sclerosis (MS) have been reported in patients with autoinflammatory diseases (AID) and variants of the NLRP3-, MEFV-, or TNFRSF1A gene. However, type and frequency of neurological involvement are widely undetermined.
METHODS
METHODS
We assessed clinical characteristics of 151 (108 with MS) patients carrying NLRP3-, MEFV- and TNFRSF1A low-penetrance variants from the Institute of Clinical Neuroimmunology. We evaluated demographic, genetic, and clinical features with a focus on central nervous system (CNS) involvement including magnetic resonance imaging (MRI) results and cerebrospinal fluid (CSF) data. The disease course of AID patients with MS was compared to a matched MS control group without mutations.
RESULTS
RESULTS
The genetic distribution comprised 36 patients (23%) with NLRP3- and 66 patients (43%) with TNFRSF1A low-penetrance variants as well as 53 (34%) patients carrying pathogenic mutations or low-penetrance variants in the MEFV gene. MS patients displayed most frequently the R92Q TNFRSF1A variant (n = 51; 46%) followed by the Q703K NLRP3 variant (n = 15; 14%) and the E148Q substitution (n = 9; 8%) in the MEFV gene. The disease course of MS was not influenced by the genetic variants and did not differ from MS patients (n = 51) without mutations. AID patients without MS most frequently harbored MEFV mutations (n = 19, 43%) followed by NLRP3- (n = 17, 39%) and TNFRSF1A (n = 8, 18%) low-penetrance variants. Sixteen (36%) of them suffered from severe CNS involvement predominantly recurrent aseptic meningoencephalitis and optic neuritis accompanied by abnormal MRI and CSF results. Severe CNS inflammation was associated with the Q703K allele. Headache was a highly prevalent neurological symptom (up to 74%), irrespective of the underlying genetic variation. The NLRP3 cohort without MS more frequently exhibited affections of the cranial nerves (CN) (p = 0.0228) and motor symptoms (p = 0.0455). Elevated acute-phase reactants were detected in all patients, and fever episodes were present in up to 50%. Arthralgias were the most frequently identified constitutional symptom among all subgroups.
CONCLUSIONS
CONCLUSIONS
Our data highlight the high prevalence of neurological manifestations, including concomitant MS, among NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants. In particular, patients carrying the Q703K NLRP3 variant are at risk for severe CNS inflammation and CN affection.
Identifiants
pubmed: 32563262
doi: 10.1186/s12974-020-01867-5
pii: 10.1186/s12974-020-01867-5
pmc: PMC7306142
doi:
Substances chimiques
NLR Family, Pyrin Domain-Containing 3 Protein
0
Pyrin
0
Receptors, Tumor Necrosis Factor, Type I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
196Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 01ZZ1603[A-D] and Z1804[A-H] (DIFUTURE)
Organisme : Deutsche Forschungsgemeinschaft
ID : EXC 1010 SyNergy
Références
Ann Rheum Dis. 2014 Dec;73(12):2160-7
pubmed: 23965844
Arthritis Rheum. 2007 Apr;56(4):1273-1285
pubmed: 17393462
J Rheumatol. 2016 Jun;43(6):1093-100
pubmed: 27036377
Nat Genet. 2001 Nov;29(3):301-5
pubmed: 11687797
Am J Med. 1988 Nov;85(5):715-7
pubmed: 3055980
Neurology. 2007 May 15;68(20):1742-4
pubmed: 17360963
Orphanet J Rare Dis. 2017 Feb 14;12(1):33
pubmed: 28196516
Nature. 2014 Sep 11;513(7517):237-41
pubmed: 24919149
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10480-5
pubmed: 22699511
Neurology. 2016 Jan 19;86(3):241-4
pubmed: 26683645
J Neurol. 2006 Jul;253(7):928-34
pubmed: 16511642
J Neurol. 1997 Aug;244(8):510-4
pubmed: 9309558
Neurology. 1990 Nov;40(11):1735-9
pubmed: 2234430
Arthritis Rheum. 2006 Aug;54(8):2674-87
pubmed: 16871532
Clin Exp Rheumatol. 2012 Nov-Dec;30(6):943-6
pubmed: 22935299
Int Immunol. 2019 Sep 18;31(10):649-655
pubmed: 31185077
Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):E7766-E7775
pubmed: 28847925
Curr Opin Rheumatol. 2005 Sep;17(5):586-99
pubmed: 16093838
Mult Scler. 2012 Sep;18(9):1229-38
pubmed: 22337722
PLoS One. 2012;7(4):e34977
pubmed: 22529966
J Neuroimmunol. 2011 May;234(1-2):1-6
pubmed: 21474190
Neuropediatrics. 2017 Apr;48(2):79-85
pubmed: 27656843
J Neuroimmunol. 2014 May 15;270(1-2):56-60
pubmed: 24657029
Brain. 2000 Oct;123 ( Pt 10):2005-19
pubmed: 11004118
J Neuroinflammation. 2015 Feb 03;12:21
pubmed: 25644504
Front Immunol. 2017 Jan 27;8:43
pubmed: 28191008
Sci Rep. 2016 Feb 19;6:20998
pubmed: 26893104
Pediatr Neurol. 1993 Jul-Aug;9(4):301-2
pubmed: 8216544
Ann Rheum Dis. 2015 Nov;74(11):2043-9
pubmed: 25038238
Nat Genet. 2009 Jul;41(7):776-82
pubmed: 19525953
Ann Rheum Dis. 2004 Oct;63(10):1356-7
pubmed: 15361406
Arthritis Rheum. 2008 Mar;58(3):888-94
pubmed: 18311798
Cephalalgia. 2016 Dec;36(14):1392-1396
pubmed: 26848126
Ann Rheum Dis. 2019 Aug;78(8):1025-1032
pubmed: 31018962
J Neuroinflammation. 2019 Apr 10;16(1):78
pubmed: 30971286
Hum Mutat. 2000 Apr;15(4):385-6
pubmed: 10737995
Eur J Neurol. 2016 Jul;23(7):1145-51
pubmed: 26931528
Eur J Paediatr Neurol. 2019 May;23(3):466-472
pubmed: 30967326
Eur J Paediatr Neurol. 2018 Jan;22(1):72-81
pubmed: 28927886
Neurology. 2008 Nov 25;71(22):1812-20
pubmed: 19029521
J Rheumatol. 2013 Mar;40(3):261-4
pubmed: 23322460
Neurology. 2005 Apr 12;64(7):1144-51
pubmed: 15824338
Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):82-85
pubmed: 29148409
Annu Rev Immunol. 2009;27:621-68
pubmed: 19302049
Neurology. 2010 Apr 20;74(16):1267-70
pubmed: 20404307
Arthritis Rheum. 2007 Aug;56(8):2774-83
pubmed: 17665448
Clin Immunol. 2019 Jun;203:45-52
pubmed: 30974290
Front Immunol. 2019 Apr 12;10:763
pubmed: 31031761
Neurol Neuroimmunol Neuroinflamm. 2015 May 14;2(4):e109
pubmed: 26020059
Rheumatology (Oxford). 2009 Dec;48(12):1618-9
pubmed: 19828598